The clinical and financial burden of non-alcoholic fatty liver disease (NAFLD) is rising, with a global prevalence of approximately 25% (1) . NAFLD encompasses a wide disease spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis.
The progression to advanced fibrosis occurs in only a small subset of patients, but represents a poor prognostic indicator, associated with increased liver-related mortality (2) .
Screening for liver disease severity is therefore vital to appropriately select patients who require dedicated hepatological follow-up.
Although histology remains the gold standard for disease staging (3), the high prevalence of NAFLD and relatively low severity in the majority of patients, makes liver biopsy an inappropriate first-line diagnostic tool. In recent years, there has been a rapid surge in the development of non-invasive tests for staging of hepatic fibrosis in NAFLD. The strength of a non-invasive test for NAFLD lies in its ability to accurately risk-stratify patients, enabling improved selection of those requiring secondary care referral or further investigations (4).
The Fibrosis 4 index (FIB-4) and NAFLD fibrosis score (NFS) are the most commonly used simple non-invasive scores for fibrosis assessment in NAFLD and are composed of readily available clinical and laboratory variables. They are designed to assess the presence of advanced fibrosis (≥F3) and have dual cut-offs, namely a high cut-off with high sensitivity and a low cut-off with high specificity. Their main utility is in ruling out advanced fibrosis with excellent negative predictive value/likelihood ratio. Therefore, they are increasingly being used as early screening tools in patients with NAFLD for the exclusion of advanced Transient elastography (Fibroscan) is the most validated elastography-based technique for fibrosis assessment in NAFLD (6) . Acoustic Radiation Forced Impulse (ARFI) is an alternative elastography technique, which has comparable diagnostic accuracy to Fibroscan for the detection of advanced fibrosis and cirrhosis (7) . Falsely elevated liver stiffness measurements (LSM) can occur in a range of conditions, including acute hepatitis, extrahepatic cholestasis, congestive heart failure, hepatic amyloidosis, and recent food intake (8) . Obesity and the presence of steatosis can also influence diagnostic accuracy, prompting the development of a dedicated XL probe for obese patients (9) .
In their study of 315 Asian patients with biopsy-proven NAFLD, Joo and co-authors, compared the diagnostic accuracy of a variety of non-invasive tests to detect advanced fibrosis and the potential influence of steatosis and other metabolic comorbidities such as obesity and the presence of metabolic syndrome. These tests included acoustic radiation force impulse imaging (ARFI) to obtain LSM, AST to ALT ratio (AAR), AST to PLT ratio index (APRI), FIB-4, NFS and BARD index (Body Mass Index, AST/ALT ratio, Diabetes) (10).
The cohort in the study included patients with an appropriate spectrum of disease; F1-F2 and advanced fibrosis (≥F3) were present in 65.4% and 17.4% of patients respectively, while steatosis severity was equally distributed with a third of patients having mild, moderate and severe steatosis respectively.
Dual cut-off values were used for FIB-4 and NFS to 'rule in' or 'rule out' patients with advanced fibrosis (10) . Comparing the areas under receiver operating characteristic curve (AUROC), the authors identified FIB-4 to have the best diagnostic accuracy for ruling out advanced fibrosis (NPV 94%, AUROC 0.87). The study confirmed that negative predictive values (NPV) of FIB-4, NFS and ARFI were all high, in contrast to relatively modest sensitivities and positive predictive values (PPV), therefore these tests appear best placed in clinical practice to indicate the absence of advanced fibrosis rather than to diagnose it. As already established, NFS and FIB4 were significantly better than APRI, AAR and BARD (11) and interestingly they had similar negative predictive values with ARFI (10).
The severity of radiological steatosis was the only independent factor affecting the AUROC (14) . Future studies are required to validate this.
In conclusion, the study by Joo confirms the excellent negative predictive value of FIB-4 and NFS in ruling out advanced fibrosis in patients with NAFLD, which is not affected by the presence of severe steatosis, thus supporting their use as 'rule out' tests. However, the rate of false positive readings, assessed by simple non-invasive tests or ARFI to a lesser extent, does appear to increase in the context of severe steatosis, therefore caution should be applied when interpreting results in this patient group. Correcting LSM for the presence of steatosis may potentially help to improve diagnostic test accuracy particularly in lesser fibrosis stages, but further investigation is required.
